SIERRA trial updates: apamistamab in AML

Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD, outlines key updates in the treatment of leukemia as presented at this year's Transplantation & Cellular Therapy (TCT) 2021 meeting including two abstracts evaluating the use of targeted radioimmunotherapy with an anti-CD45 antibody, apamistamab (Iomab-B) in patients with acute myeloid leukemia. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

• #education
• #speaker_tania_jain
• #institution_johns_hopkins_university
• #event_vjvirtual
• #event_tct_2021
• #format_interview
• #subject_leukemia
• #subject_acute_myeloid_leukemia
• #field_treatment
• #field_trial_updates
• #field_transplantation
• #field_immuno_oncology
• #medicines_apamistamab
• #trial_sierra
• #nct02665065